Merck & Co Shares downgraded from outperform to market perform by BMO analyst

|


Shares downgraded from outperform to market perform by BMO analyst

  • Street’s high expectations and an over-dependence on Keytruda, plus competitor trials, makes for a balanced stock risk/reward says Alex Arfaei, BMO analyst.
  • Shares are signified lower – ask $75.45 against prior close of $75.83.
  • Fourth quarter figures and the forecast for this year should be as expected or slightly lighter when reports issued on Feb 1 by MRK.